Granted Patent B2

US 12,533,347 · App. 18/369,737 · Granted Jan 27, 2026

Inventor: Gerald Horn (Highland Park, IL)

Assignee: LENZ THERAPEUTICS OPERATIONS, INC.

A61K31/439A61K47/02A61K47/12A61K47/14A61K47/183A61K47/186A61K47/20A61K47/22A61K47/26A61K47/38A61J1/165

Abstract

Claims (22)

1 . A method of treating presbyopia in a subject, comprising:

(a) storing an aqueous ophthalmological composition in a container at a temperature from about 2 degrees Celsius to about 8 degrees Celsius, thereby providing a stored aqueous ophthalmological composition; and

(b) administering the stored aqueous ophthalmological composition to the subject, thereby treating the presbyopia in the subject;

wherein the aqueous ophthalmological composition comprises aceclidine, lacks a cycloplegic agent, and is configured within the container, wherein the container comprises:

(i) a closure;

(ii) a vessel;

(iii) the aqueous ophthalmological composition; and

(iv) a headspace between the aqueous ophthalmological composition and the closure;

wherein the closure is configured to prevent the stored aqueous ophthalmological composition from exiting the vessel;

wherein when the container is stored at the temperature from about 2 degrees Celsius to about 8 degrees Celsius for at least 7 months, wherein the stored aqueous ophthalmological composition comprises at least 90% of the aceclidine that the composition comprised at the onset of storing; and

wherein when the container is stored at the temperature from about 2 degrees Celsius to about 8 degrees Celsius for at least 7 months, and wherein the stored aqueous ophthalmological composition is suitable for treating presbyopia after the storing.

2 . The method of claim 1 , wherein when the container is stored at the temperature from about 2 degrees Celsius to about 8 degrees Celsius for at least 12 months, wherein the stored aqueous ophthalmological composition comprises at least 90% of the aceclidine that the aqueous ophthalmological composition comprised at the onset of storing.

3 . The method of claim 1 , wherein when the container is stored at the temperature from about 2 degrees Celsius to about 8 degrees Celsius for at least 18 months, wherein the stored aqueous ophthalmological composition comprises at least 90% of the aceclidine that the aqueous ophthalmological composition comprised at the onset of storing.

4 . The method of claim 1 , wherein when the container is stored at the temperature from about 2 degrees Celsius to about 8 degrees Celsius for at least 24 months, wherein the stored aqueous ophthalmological composition comprises at least 90% of the aceclidine that the aqueous ophthalmological composition comprised at the onset of storing.

5 . The method of claim 1 , wherein the aqueous ophthalmological composition has a viscosity of about 1 centipoise (cp) to about 25 cps at a high shear rate of blinking and a viscosity of about 50 cps to about 200 cps at a low shear rate between blinks.

6 . The method of claim 1 , wherein the aqueous ophthalmological composition has a pH from about 4.0 to about 8.0.

7 . The method of claim 6 , wherein the pH is from about 5.0 to about 7.0.

8 . The method of claim 1 , wherein the aceclidine is at a concentration from about 0.25% to about 4.0% w/v, wherein w/v denotes weight by total volume of the aqueous ophthalmological composition.

9 . The method of claim 8 , wherein the aceclidine is at a concentration from about 0.25% to about 2.0% w/v, wherein w/v denotes weight by total volume of the aqueous ophthalmological composition.

10 . The method of claim 9 , wherein the aceclidine is at a concentration from about 0.5% to about 1.9% w/v, wherein w/v denotes weight by total volume of the aqueous ophthalmological composition.

11 . The method of claim 1 , wherein the aqueous ophthalmological composition further comprises a surfactant.

12 . The method of claim 1 , wherein the aqueous ophthalmological composition further comprises a viscosity agent.

Assignments (2)

Continuity (6)

References Cited (291)